Figure 9
Effect of 5-HT1A-R Antagonist (NAN-190) or Dopamine D-2R Antagonist (Fluspirilene) with or without the Most Stimulatory Dose of 5-HT or Dopamine on NCC Migration. The graph shows Rd/c of NCCs treated with antagonists with or without the most stimulatory dose of 5-HT or dopamine. (A) Maximum increase in the mean velocity of FMB-NCCs after the addition of 5-HT was observed at 0.1 μM (Figure 7A). NAN-190 (0.1 μM) markedly decreased the stimulatory effect of 0.1 μM 5-HT, which was reduced to control levels. There were no statistically significant differences between FMB-NCCs after the treatment of antagonist alone (0.1 μM NAN-190) and control in Rd/c (cont: n = 201; 0.1 μM NAN-190: n = 43, P = 0.424; 0.1 μM 5-HT + 0.1 μM NAN-190: n = 39, P = 0.873). In the case of dopamine, the maximum effect was observed at 0.1 μM (Figure 8A). And 30 μM Fluspirilene decreased the stimulatory effect of 0.1 μM dopamine markedly, to control levels. There were no statistically significant differences between FMB-NCCs after the treatment of antagonist alone (30 μM Fluspirilene) and control in Rd/c (cont: n = 201; 30 μM Fluspirilene: n = 43, P = 0.76; 0.1 μM dopamine + 30 μM Fluspirilene: n = 64, P = 0.526). (B) The "mean velocity" of HB-NCCs increased after the addition of dopamine at 0.1 μM (Figure 8B). Fluspirilene (30 μM) decreased the stimulatory effect of 0.1 μM dopamine markedly, to control levels. This amount of Fluspirilene alone caused no significant difference from the control (cont: n = 417; 30 μM Fluspirilene: n = 100, P = 0.757; 0.1 μM dopamine + 30 μM Fluspirilene: n = 17, P = 0.877).